Goldman Sachs Sell-side卖方

Royalty Pharma Plc (RPRX) Steady Outperformance, Another Beat and Raise

Aug 6, 20268 pages页

From the report报告摘录Beat & Raised Guidance: RPRX beats FY2026 estimates ($773mn vs $754mn portfolio receipts), raises guidance to $3.4bn–$3.5bn (7–10% royalty growth), valuation upgraded to $66 (12.5x EV/EBITDA).

Read the full report + PDF阅读全文与 PDF

The full summary (4 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（4 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →